161 related articles for article (PubMed ID: 14655599)
41. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
42. Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?
Armatys SA; Koch MO; Bihrle R; Gardner TA; Cheng L
BJU Int; 2005 Oct; 96(6):777-80. PubMed ID: 16153198
[TBL] [Abstract][Full Text] [Related]
43. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
44. [Histological classification of prostatic cancer].
Sakamoto A; Terado Y
Nihon Rinsho; 1998 Aug; 56(8):1959-62. PubMed ID: 9750487
[TBL] [Abstract][Full Text] [Related]
45. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
Osunkoya AO; Nielsen ME; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):468-72. PubMed ID: 18300802
[TBL] [Abstract][Full Text] [Related]
46. Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease.
Bright EA; Manuel C; Goddard JC; Khan MA
Urol Int; 2009; 83(2):171-4. PubMed ID: 19752612
[TBL] [Abstract][Full Text] [Related]
47. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
48. 'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases.
Bostwick DG; Bostwick KC
BJU Int; 2004 Jul; 94(1):57-8. PubMed ID: 15217431
[TBL] [Abstract][Full Text] [Related]
49. [Classification of "accidentally-detected" cancer of the prostate based on the data of repeated transurethral resection].
Kopper B; Dom G; Mast G; Tsigler M
Urol Nefrol (Mosk); 1985; (5):42-4. PubMed ID: 2414887
[No Abstract] [Full Text] [Related]
50. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
51. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
[TBL] [Abstract][Full Text] [Related]
52. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.
Okihara K; Nakanishi H; Nakamura T; Mizutani Y; Kawauchi A; Miki T
Int J Urol; 2005 Jul; 12(7):662-7. PubMed ID: 16045559
[TBL] [Abstract][Full Text] [Related]
53. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
54. [One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia].
Karaguzhin SG; Merinov DS; Martov AG
Urologiia; 2005; (5):17-21. PubMed ID: 16281833
[TBL] [Abstract][Full Text] [Related]
55. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
56. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
57. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
58. [Prognosis of incidental (stage A) prostatic cancer].
Uchida T; Go M; Egawa S; Ao T; Kuwao S; Yokoyama E; Mashimo S; Endo T; Koshiba K
Nihon Hinyokika Gakkai Zasshi; 1993 Jul; 84(7):1293-300. PubMed ID: 7689124
[TBL] [Abstract][Full Text] [Related]
59. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
60. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
